Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).

Bioequivalence: Overview

Bioequivalence: Overview

Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...

Dose-Response Relationship: Potency and Efficacy

Dose-Response Relationship: Potency and Efficacy

The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it produces...

Pharmacodynamic Models: Linear Concentration–Effect Model

Pharmacodynamic Models: Linear Concentration–Effect Model

The linear concentration–effect model, underpinned by the principle that pharmacological effect (E) is directly proportional to plasma drug concentration (C), emerges as a pivotal simplification of the Emax model for conditions where C is significantly less than EC50. This model portrays a linear trajectory of the concentration–effect relationship when drug levels are markedly below the EC50 threshold.Despite its inherent assumption of continuous effect augmentation with increasing drug...

Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems

Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems

Bioavailability is a critical pharmacological concept that measures the extent and rate at which an active drug ingredient or therapeutic moiety enters the systemic circulation, remaining unchanged. It's a pivotal factor in determining a drug's efficacy and safety.The Biopharmaceutics Classification System (BCS) plays an essential role in drug development by categorizing drugs into four classes based on their solubility and permeability. This classification aids in understanding drug absorption...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Relaxor behavior in rocksalt cation-ordered material induced by (anti)ferroelectric phase competition.

Nature communications·2026

Same author

Chromatin- and actin-mediated mitochondrial streaming leads to patterning of mitochondrial distribution in oocytes.

Nature communications·2026

Same author

Contemporary Operator Procedural Volumes and Outcomes for TAVR and MTEER in the US.

JAMA cardiology·2026

Same author

Colossal and tunable dielectric tunability in domain-engineered barium strontium titanate.

Nature communications·2025

Same author

Redox-dependent binding and conformational equilibria govern the fluorescence decay of NAD(P)H in living cells.

FEBS letters·2025

Same author

Strain-induced lead-free morphotropic phase boundary.

Nature communications·2025

Search research articles

Related Experiment Video

Updated: May 23, 2026

Cost-Efficient Transcriptomic-Based Drug Screening

Cost-Efficient Transcriptomic-Based Drug Screening

Published on: February 23, 2024

Cost-effectiveness: an evolving science.

Biotechnology Healthcare

|April 6, 2012

Summary

This summary is machine-generated.

Government payers internationally require biopharmaceutical companies to demonstrate cost-effectiveness. This international collaboration offers a potential model for U.S. healthcare payers and drug manufacturers.

More Related Videos

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents

Published on: September 10, 2018

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease

Published on: August 9, 2024

Related Experiment Videos

Last Updated: May 23, 2026

Cost-Efficient Transcriptomic-Based Drug Screening

Cost-Efficient Transcriptomic-Based Drug Screening

Published on: February 23, 2024

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents

Published on: September 10, 2018

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease

Published on: August 9, 2024

Area of Science:

Health economics
Pharmaceutical policy
Biopharmaceutical industry

Background:

Government payers globally are increasingly demanding evidence of cost-effectiveness from biopharmaceutical companies.
The need for robust health economic data is a growing challenge for drug manufacturers seeking market access.

Purpose of the Study:

To examine international models of payer-manufacturer collaboration on cost-effectiveness evidence generation.
To identify potential strategies for U.S. payers and manufacturers to address evolving evidence requirements.

Main Methods:

Analysis of international healthcare payer policies regarding cost-effectiveness data.
Case studies of successful collaborations between government payers and biopharmaceutical companies.
Review of economic evaluation methodologies used in different healthcare systems.

Main Results:

Overseas, government payers actively challenge biopharma companies to provide compelling cost-effectiveness data.
Collaborative approaches between payers and manufacturers have emerged as a viable strategy in some international markets.
These collaborations facilitate the generation and acceptance of relevant economic evidence.

Conclusions:

International experiences suggest that proactive collaboration can help biopharmaceutical companies meet payer demands for cost-effectiveness evidence.
The U.S. healthcare system could benefit from adopting similar collaborative models to navigate evidence requirements.
Fostering partnerships between U.S. payers and manufacturers is crucial for demonstrating the value of innovative therapies.